Genfit : 10 June crucial for the group
>€ 89m to come from Ipsen in 2024, ensuring financial visibility out to end-2025 - Yesterday evening, Genfit published 2023 annual results that beat our expectations. Operating profit was € 38m, including € 13m billed to Ipsen, € 9m in revenue from the partial recognition of the € 40m paid in 2021 and € 6.5m in services for the latter. Research grants and tax credits help to supplement revenue. Conversely, R&D spend rose significantly over the year, up to € 46.5m...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.